- Home
- SPFI vs KURA Comparison
SPFI vs KURA Comparison
Compare SPFI & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | KURA |
|---|---|---|
| Founded | 1941 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 794.2M | 841.6M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | SPFI | KURA |
|---|---|---|
| Price | $44.72 | $10.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $46.00 | $25.56 |
| AVG Volume (30 Days) | 184.2K | ★ 1.6M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.68% | N/A |
| EPS Growth | ★ 17.81 | N/A |
| EPS | ★ 0.85 | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | $22.65 | $28.28 |
| Revenue Next Year | $9.40 | $106.37 |
| P/E Ratio | $52.06 | ★ N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $35.34 | $5.45 |
| 52 Week High | $46.94 | $12.49 |
Technical Indicators
Market Signals| Indicator | SPFI | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 59.74 | 45.11 |
| Support Level | $39.06 | $8.53 |
| Resistance Level | $46.94 | $10.97 |
| Average True Range (ATR) | 1.40 | 0.52 |
| MACD | 0.10 | -0.17 |
| Stochastic Oscillator | 60.78 | 8.33 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking. The majority of the company's revenues is derived from interest income and other sources, including loans, securities and derivatives.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.